- Home
- /
- News
- /
- Biotherapeutics
- /
- July 2020
Biotherapeutics News for July 2020
New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
27 July, 2020
Amsterdam, The Netherlands, 23 June 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has been awarded a €3.1 million Innovation Credit from the Dutch Government. The funds will be used to advance the Company’s lead CD47/QPCTL immuno-oncology program through preclinical development towards human clinical studies.
15 July, 2020
CPI today announced a partnership with Excivion Ltd, Cambridge, to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX, an integral component of any future vaccine formulation. Excivion’s technology could help to prevent future pandemics of deadly viruses by avoiding the adverse immune responses common in current vaccine candidates for Zika and related viruses.
13 July, 2020